Pharmaceutical

ICTCAR-028 by Innovative Cellular Therapeutics for Hematological Tumor: Likelihood of Approval

ICTCAR-028 is under clinical development by Innovative Cellular Therapeutics and currently in Phase III for Hematological Tumor.

Jul 6, 2024 - 04:00
ICTCAR-028 is under clinical development by Innovative Cellular Therapeutics and currently in Phase III for Hematological Tumor.
Read the original article

Tags:

Previous Article

CAN-3110 by Candel Therapeutics for High-Grade Glioma: Likelihood of Approval

Next Article

LP-184 by Starlight Therapeutics for Non-Small Cell Lung Cancer: Likelihood of A...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sirolimus by OrphAI Therapeutics for Pulmonary Arterial...

Dec 6, 2023

STAT+: Harvard longevity scientist sparks furor with claim about reversing aging in dogs

STAT+: Harvard longevity scientist sparks furor with cl...

Mar 6, 2024

STAT+: FDA OKs — but doesn’t require — a non-cancer-causing chemical for sterilizing devices

STAT+: FDA OKs — but doesn’t require — a non-cancer-cau...

Jan 24, 2024